Power Morcellator News: Bernstein Liebhard LLP Notes Criticism of Latest FDA Uterine Morcellation Warning

Share Article

The doctor who is spearheading a petition to ban power morcellators says the FDA’s most recent warning is not enough to protect hysterectomy and fibroid removal patients from the risk of spreading uterine cancer.

Free Case Review
ince the launch of their campaign, our Firm has heard from numerous women who allegedly experienced the spread of uterine sarcomas and other cancers due to power morcellators.

The physician who has done so much to bring attention to the dangers potentially associated with surgical tools called power morcellators (http://www.morcellatorlawsuit2015.com/ ) asserts that federal regulators still have not done enough to ensure more women won’t be stricken with advanced-staged cancer following minimally-invasive hysterectomy and fibroid removal procedures. According to USAToday, Hooman Noorchashm insists that as long as power morcellators are allowed to remain on the market, patients will remain at risk.*

Dr. Noorchashm began working for a uterine morcellation ban last fall, after his wife, Dr. Amy Reed, was diagnosed with Stage 4 uterine cancer shortly after she underwent a morcellator hysterectomy to remove fibroids. According to USAToday, Dr. Reed is among about two dozen women who in the past year have claimed that their cancer was spread via uterine morcellation. Shortly after his wife was diagnosed, Dr. Noorchashm launched a Change.org petition to ban the devices that has so far collected more than 86,000 signatures.**

“It’s unlikely that this issue ever would have received the attention it deserves without the work of Drs. Noorchashm and Dr. Reed. Since the launch of their campaign, our Firm has heard from numerous women who allegedly experienced the spread of uterine sarcomas and other cancers due to power morcellators,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is providing free legal consultations to women who were diagnosed with advanced uterine cancers following uterine morcellation.

Power Morcellators and Cancer
Power morcellators are used in laparoscopic hysterectomy and fibroid removal procedures to shred tissue so that it may be removed via a small abdominal incision. The U.S. Food & Drug Administration (FDA) has been reviewing the association between uterine morcellation and cancer since April, when it first discouraged the use of the devices.*** On November 24th, the agency issued a second alert that warned against the use of the devices in most women, and asked power morcellator manufacturers to add a new black box warning – the strongest possible safety notice – regarding this life-threatening complication to their labels.

In its most recent morcellator cancer warning, the FDA noted that the prevalence of unsuspected uterine sarcoma in patients undergoing hysterectomy or fibroid removal surgery is 1 in 352, while the prevalence of unsuspected uterine leiomyosarcoma is 1 in 498. Both of these estimates are higher than the clinical community previously understood. A power morcellator can disseminate these cells beyond the uterus, upstaging the disease and greatly reducing a woman’s chances for long-term survival, the agency said.

Women who allegedly experienced the spread of uterine cancers due to a power morcellator may be eligible to pursue a morcellator lawsuit to obtain compensation for medical bills, lost wages, pain and suffering and other damages. To learn more, please visit Bernstein Liebhard LLP's website. To obtain a free legal review, please call 800-511-5092.

*usatoday.com/story/news/nation/2014/11/24/fda-warning-power-morcellator-fibroids-cancer/19491165/, USAToday, November 26, 2014
**http://www.change.org/p/women-s-health-alert-deadly-cancers-of-the-uterus-spread-by-gynecologists-stop-morcellating-the-uterus-in-minimally-invasive-and-robot-assisted-hysterectomy, Change.org
***fda.gov/medicaldevices/safety/alertsandnotices/ucm393576.htm, FDA, April 17, 2014

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Felecia L. Stern
Visit website